Clinical trial – www.brainwork.md

9th July 2019

Treating nature with NURTURE: Interim results of nusinersen for SMA

https://www.brainwork.md/content/uploads/2019/07/Brainwork-NURTURE.jpg 3473 2300 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 9th July 2019 9th July 2019

Promising results for a disease-modifying treatment for spinal muscular atrophy (SMA) were presented at the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, last week.…

Mea Holm, PhD
0
0

9th July 2019

Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

https://www.brainwork.md/content/uploads/2019/07/Brainwork-Natalizumab.jpg 3067 2300 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 9th July 2019 9th July 2019

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

Michael Furrer, PhD
0
0

4th July 2019

8-year follow-up data of alemtuzumab presented

https://www.brainwork.md/content/uploads/2019/07/follow-up-data-of-alemtuzumab-presented-image.jpg 1920 1280 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 4th July 2019 9th July 2019

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

Michael Furrer, PhD
0
0

20th June 2019

Machine-learning algorithm predicts psychosis from speech

https://www.brainwork.md/content/uploads/2019/06/Brainwork-MachineLearning.jpg 3150 2100 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 20th June 2019 19th June 2019

Algorithms designed to find hidden clues within everyday language can predict those at risk of developing psychosis, a new study reports. Using machine learning, researchers from the Department of Psychology…

Peter Stevenson, PhD
0
0

30th November 2018

Gene therapy shows promise in Parkinson’s disease

https://www.brainwork.md/content/uploads/2018/11/Brainwork-ParkinsonsPromise.jpg 2100 1400 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 30th November 2018 30th November 2018

Interim results from a Phase Ib trial show that gene therapy may reduce the need for medication in patients with Parkinson’s disease refractory to levodopa. The investigational therapy is designed…

Mea Holm, PhD
0
0

16th October 2018

Serum neurofilament light: A biomarker for disease activity in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustration-soluble-biomarkers-V00-03-20181012.jpg 1920 1080 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 16th October 2018 19th October 2018

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

Mea Holm, PhD
1
0

15th October 2018

Results from the MS-SMART trial unveiled

https://www.brainwork.md/content/uploads/2018/10/Brainwork-ECTRIMSSMART.jpg 3971 2975 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 15th October 2018 15th October 2018

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

Mea Holm, PhD
0
0

11th October 2018

FLOODLIGHT offers illuminating outcomes for smartphone monitoring in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustrations-articles-Floodlight-V00-01-20181011-01-1.jpg 1920 1080 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 11th October 2018 11th October 2018

Smartphone-based, high-yield active and passive self-monitoring of multiple sclerosis (MS) may enhance clinical disease assessments when compared to conventional methods for detecting subtle progressive clinical changes, according to a study…

Peter Stevenson, PhD
1
0

1st October 2018

Restoring “conductor” cells in the orchestra of schizophrenia

https://www.brainwork.md/content/uploads/2018/10/Brainwork-Orchestra.jpg 2850 1900 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 1st October 2018 1st October 2018

Key symptoms of schizophrenia, including hallucinations, hyperactivity and impaired memory, could be caused by desynchronised cells in the brain, recent research published in Nature Neuroscience has revealed. The authors investigated…

Peter Stevenson, PhD
0
1

19th September 2018

Quarterly migraine injection approved in US

https://www.brainwork.md/content/uploads/2018/09/Brainwork-FDAApprovesMigraine.jpg 2885 1900 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 19th September 2018 19th September 2018

The US FDA has approved a new humanised monoclonal antibody for migraine prevention in adults. Fremanezumab-vfrm – under the brand name AJOVYTM (Teva Pharmaceuticals) – prevents the interaction between calcitonin…

Peter Stevenson, PhD
1
0